ES2312978T3 - Potenciador del efecto antitumoral y agente antitumoral. - Google Patents
Potenciador del efecto antitumoral y agente antitumoral. Download PDFInfo
- Publication number
- ES2312978T3 ES2312978T3 ES04719589T ES04719589T ES2312978T3 ES 2312978 T3 ES2312978 T3 ES 2312978T3 ES 04719589 T ES04719589 T ES 04719589T ES 04719589 T ES04719589 T ES 04719589T ES 2312978 T3 ES2312978 T3 ES 2312978T3
- Authority
- ES
- Spain
- Prior art keywords
- antitumor
- tegafur
- effect
- potassium
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-70097 | 2003-03-14 | ||
| JP2003070097 | 2003-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2312978T3 true ES2312978T3 (es) | 2009-03-01 |
Family
ID=32984641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04719589T Expired - Lifetime ES2312978T3 (es) | 2003-03-14 | 2004-03-11 | Potenciador del efecto antitumoral y agente antitumoral. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9611227B2 (enExample) |
| EP (1) | EP1604991B1 (enExample) |
| JP (1) | JP4610481B2 (enExample) |
| KR (1) | KR100812693B1 (enExample) |
| CN (2) | CN101357134A (enExample) |
| AT (1) | ATE408408T1 (enExample) |
| AU (1) | AU2004220205B2 (enExample) |
| BR (1) | BRPI0408372A (enExample) |
| CA (1) | CA2518195C (enExample) |
| CY (1) | CY1108395T1 (enExample) |
| DE (1) | DE602004016636D1 (enExample) |
| DK (1) | DK1604991T3 (enExample) |
| ES (1) | ES2312978T3 (enExample) |
| MX (1) | MXPA05009781A (enExample) |
| NZ (1) | NZ542150A (enExample) |
| PL (1) | PL1604991T3 (enExample) |
| PT (1) | PT1604991E (enExample) |
| RU (1) | RU2334517C2 (enExample) |
| SI (1) | SI1604991T1 (enExample) |
| TW (1) | TW200503720A (enExample) |
| WO (1) | WO2004081012A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2603809C (en) * | 2005-04-01 | 2011-12-06 | Taiho Pharmaceutical Co., Ltd. | Radiotherapy enhancer |
| CA2603810C (en) * | 2005-04-01 | 2012-06-26 | Taiho Pharmaceutical Co., Ltd. | Potentiator for radiation therapy comprising pyridine derivative as active ingredient |
| JPWO2007043531A1 (ja) * | 2005-10-07 | 2009-04-16 | セレスター・レキシコ・サイエンシズ株式会社 | 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用 |
| WO2009139085A1 (ja) * | 2008-05-12 | 2009-11-19 | 静岡県 | 抗腫瘍剤、キット及び癌治療方法 |
| JP5553522B2 (ja) * | 2009-03-31 | 2014-07-16 | 大鵬薬品工業株式会社 | 経口投与用医薬組成物 |
| EP2422785B1 (en) * | 2009-04-22 | 2019-11-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of chemotherapy on renal cell cancer |
| CN102309491B (zh) * | 2010-07-02 | 2015-06-10 | 天津金耀集团有限公司 | 一种替加氟、吉美斯特复方注射液 |
| MX353289B (es) * | 2011-05-25 | 2018-01-05 | Taiho Pharmaceutical Co Ltd | Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico. |
| US9694001B2 (en) * | 2013-09-30 | 2017-07-04 | Taiho Pharmaceutical Co., Ltd. | Combination therapy using azabicyclo compound for cancer |
| CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
| CN106581001B (zh) * | 2016-11-03 | 2018-12-21 | 江苏恒瑞医药股份有限公司 | 一种替吉奥组合物的制备方法 |
| KR102258514B1 (ko) | 2019-09-23 | 2021-05-31 | 연세대학교 산학협력단 | 신규한 다층형 좌약 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0443028B1 (en) | 1989-01-05 | 1993-09-29 | Otsuka Pharmaceutical Co., Ltd. | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer |
| DE10299023I2 (de) * | 1990-09-07 | 2010-05-06 | Tahio Pharmaceutical Co Ltd | Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff |
| CA2087540C (en) * | 1991-05-27 | 1999-01-19 | Tetsuhiko Shirasaka | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| CH683262A5 (it) * | 1992-01-22 | 1994-02-15 | Applied Pharma Res | Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico). |
| WO2001066102A2 (en) * | 2000-03-08 | 2001-09-13 | Bristol-Myers Squibb Company | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| BR0207443A (pt) | 2001-03-06 | 2004-04-06 | Bristol Myeres Squibb Company | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina |
| EP1411120B1 (en) * | 2001-07-05 | 2010-01-13 | Taiho Pharmaceutical Company Limited | Dna arrays for measuring sensitivity to anticancer agent |
-
2004
- 2004-03-11 NZ NZ542150A patent/NZ542150A/xx not_active IP Right Cessation
- 2004-03-11 DK DK04719589T patent/DK1604991T3/da active
- 2004-03-11 RU RU2005131839/15A patent/RU2334517C2/ru active
- 2004-03-11 SI SI200430955T patent/SI1604991T1/sl unknown
- 2004-03-11 PL PL04719589T patent/PL1604991T3/pl unknown
- 2004-03-11 DE DE602004016636T patent/DE602004016636D1/de not_active Expired - Lifetime
- 2004-03-11 PT PT04719589T patent/PT1604991E/pt unknown
- 2004-03-11 CA CA002518195A patent/CA2518195C/en not_active Expired - Fee Related
- 2004-03-11 JP JP2005503567A patent/JP4610481B2/ja not_active Expired - Lifetime
- 2004-03-11 WO PCT/JP2004/003189 patent/WO2004081012A1/ja not_active Ceased
- 2004-03-11 BR BRPI0408372-5A patent/BRPI0408372A/pt not_active Application Discontinuation
- 2004-03-11 CN CNA2008101445581A patent/CN101357134A/zh active Pending
- 2004-03-11 CN CNA2004800069779A patent/CN1761665A/zh active Pending
- 2004-03-11 US US10/548,655 patent/US9611227B2/en not_active Expired - Fee Related
- 2004-03-11 EP EP04719589A patent/EP1604991B1/en not_active Expired - Lifetime
- 2004-03-11 AU AU2004220205A patent/AU2004220205B2/en not_active Ceased
- 2004-03-11 KR KR1020057017150A patent/KR100812693B1/ko not_active Expired - Lifetime
- 2004-03-11 ES ES04719589T patent/ES2312978T3/es not_active Expired - Lifetime
- 2004-03-11 MX MXPA05009781A patent/MXPA05009781A/es active IP Right Grant
- 2004-03-11 AT AT04719589T patent/ATE408408T1/de active
- 2004-03-12 TW TW093106702A patent/TW200503720A/zh not_active IP Right Cessation
-
2008
- 2008-10-06 CY CY20081101101T patent/CY1108395T1/el unknown
-
2017
- 2017-02-17 US US15/435,493 patent/US9814724B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4610481B2 (ja) | 2011-01-12 |
| NZ542150A (en) | 2009-09-25 |
| CN101357134A (zh) | 2009-02-04 |
| US20060116345A1 (en) | 2006-06-01 |
| TWI295173B (enExample) | 2008-04-01 |
| DK1604991T3 (da) | 2009-01-05 |
| EP1604991A4 (en) | 2006-05-03 |
| CY1108395T1 (el) | 2014-02-12 |
| PL1604991T3 (pl) | 2009-02-27 |
| US20170157131A1 (en) | 2017-06-08 |
| CN1761665A (zh) | 2006-04-19 |
| JPWO2004081012A1 (ja) | 2006-06-08 |
| TW200503720A (en) | 2005-02-01 |
| EP1604991A1 (en) | 2005-12-14 |
| RU2005131839A (ru) | 2006-02-10 |
| MXPA05009781A (es) | 2005-10-26 |
| WO2004081012A1 (ja) | 2004-09-23 |
| PT1604991E (pt) | 2008-10-27 |
| EP1604991B1 (en) | 2008-09-17 |
| AU2004220205A1 (en) | 2004-09-23 |
| US9611227B2 (en) | 2017-04-04 |
| BRPI0408372A (pt) | 2006-03-21 |
| DE602004016636D1 (de) | 2008-10-30 |
| RU2334517C2 (ru) | 2008-09-27 |
| KR20050106119A (ko) | 2005-11-08 |
| ATE408408T1 (de) | 2008-10-15 |
| AU2004220205B2 (en) | 2010-06-17 |
| CA2518195A1 (en) | 2004-09-23 |
| KR100812693B1 (ko) | 2008-03-13 |
| CA2518195C (en) | 2009-07-07 |
| US9814724B2 (en) | 2017-11-14 |
| SI1604991T1 (sl) | 2009-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9814724B2 (en) | Antitumor effect potentiator and antitumor agent | |
| ES2333348T3 (es) | Combinaciones que comprenden epotilonas e inhibidores de la proteina tirosina quinasa y usos farmaceuticos de las mismas. | |
| ES2385850T3 (es) | Potenciador de radioterapia | |
| ES2278702T3 (es) | Composicion para el tratamiento de metastasis o del cancer, que contiene fluorouracilo y un agente de transferencia de metilol. | |
| JP2557303B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| ES2393398T3 (es) | Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer | |
| JPWO1992004028A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| TWI440464B (zh) | Anti-tumor agents, sets of groups and cancer treatment | |
| WO2013137433A1 (ja) | ３剤を組み合わせた新規な抗腫瘍剤 | |
| KR20120015318A (ko) | 테가푸르?기메라실?오테라실칼륨 배합제 및 옥살리플라틴을 함유하는 항종양제 | |
| HK1127546A (en) | Antitumor effect potentiator and antitumor agent | |
| JP2003300888A (ja) | 抗腫瘍効果増強剤 | |
| KR20100131457A (ko) | 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제 |